Alpha 2.0
Login Register
» Authors » Taylor Sandison

Taylor Sandison

Explore the profile of Taylor Sandison including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 338
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Microbiology
Top 10 Co-Authors
Shawn Flanagan
Matteo Bassetti
Patrick M Honore
Alex Soriano
Voon Ong
Oliver A Cornely
Anita F Das
George R Thompson 3rd
Peter G Pappas
John Pullman
Published In
Antimicrob Agents Chemother
Clin Infect Dis
Crit Care
Diagn Microbiol Infect Dis
Am J Prev Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin
Soriano A, Locke J, Cornely O, Roilides E, Ramos-Martinez A, Honore P, et al.
Clin Microbiol Infect . 2024 Nov; 31(2):250-257. PMID: 39581541
Objectives: A post hoc analysis used pooled STRIVE/ReSTORE trial data to determine outcomes with rezafungin versus caspofungin by Candida species and antifungal susceptibility. Methods: The efficacy and safety of once...
2.
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics
Andes D, Bruggemann R, Flanagan S, Lepak A, Lewis R, Ong V, et al.
J Antimicrob Chemother . 2024 Nov; 80(1):18-28. PMID: 39540899
Echinocandin drugs are the current first-line therapy for fungal infections caused by Candida spp. Most patients require once-daily intravenous (IV) administration in a hospital or outpatient setting for treatment, which...
3.
Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials
Honore P, Bassetti M, Cornely O, Dupont H, Fortun J, Kollef M, et al.
Crit Care . 2024 Nov; 28(1):361. PMID: 39529079
Background: Invasive candidiasis/candidemia (IC/C) is associated with a substantial health economic burden driven primarily by prolonged hospital stay. The once-weekly IV echinocandin, rezafungin acetate, has demonstrated non-inferiority to caspofungin in...
4.
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials
Honore P, Girardis M, Kollef M, Cornely O, Thompson 3rd G, Bassetti M, et al.
Crit Care . 2024 Oct; 28(1):348. PMID: 39468640
Background: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE...
5.
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study
Soriano A, Honore P, Cornely O, Chayakulkeeree M, Bassetti M, Haihui H, et al.
Clin Infect Dis . 2024 Jul; 79(3):672-681. PMID: 38985561
Background: Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure...
6.
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects
Flanagan S, Ong V, Marbury T, Jandourek A, Gandhi R, Sandison T
Pharmacotherapy . 2024 Jun; 44(6):435-443. PMID: 38840536
Introduction: Rezafungin is a second-generation, once-weekly echinocandin antifungal approved for the treatment of invasive candidiasis, including candidemia. In phase II/III studies of rezafungin versus caspofungin, patients with severe hepatic impairment...
7.
Outcomes by spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis
Locke J, Pillar C, Castanheira M, Carvalhaes C, Andes D, Aram J, et al.
Antimicrob Agents Chemother . 2024 Mar; 68(5):e0158423. PMID: 38526046
Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC...
8.
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
Thompson 3rd G, Soriano A, Honore P, Bassetti M, Cornely O, Kollef M, et al.
Lancet Infect Dis . 2023 Nov; 24(3):319-328. PMID: 38008099
Background: Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials. We...
9.
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Flanagan S, Walker H, Ong V, Sandison T
Microbiol Spectr . 2023 May; 11(3):e0133923. PMID: 37154682
Rezafungin is a novel once-weekly echinocandin for intravenous injection currently in development for the treatment of infections and the prevention of , Aspergillus, and Pneumocystis infections in allogeneic blood and...
10.
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need
Yasinskaya Y, Bala S, Waack U, Dixon C, Higgins K, Moore J, et al.
Clin Infect Dis . 2023 Apr; 77(3):380-387. PMID: 37021650
Pressing challenges in the treatment of invasive fungal infections (IFIs) include emerging and rare pathogens, resistant/refractory infections, and antifungal armamentarium limited by toxicity, drug-drug interactions, and lack of oral formulations....